Rationale: Although recent studies have suggested a role for the receptor activator of nuclear factor B ligand (RANKL) in the late stages of atherosclerosis (eg, plaque destabilization and rupture), the underlying mechanisms and subsequent events are unclear.
A therosclerosis is a well-studied chronic inflammatory disease that is characterized by thickening of the artery walls and formation of atherosclerotic plaques. 1 The later stage of atherosclerosis is accompanied by plaque destabilization and thrombus formation. 2 It is widely accepted that an abundance of active tissue factor (TF) in atherosclerotic plaques is a disastrous factor toward initiation and progression of atherothrombosis. 3, 4 Hence, finding TF regulators seems to be of importance to advanced atherosclerosis and acute coronary syndrome.
The receptor activator of nuclear factor B ligand (RANKL) was initially identified as a regulator of bone remodeling. Recently, the physiological and pathological relevance of RANKL was extended to vascular biology, including atherosclerosis. 5 RANKL exists in either a cell-bound or a secreted form and it is produced by vascular cells and activated immune cells close to blood vessels. 6 RANKL is upregulated by inflammatory cytokines such as tumor necrosis factor-␣, interleukin-1␣, and interleukin-6. 3 The mRNA level of RANKL was increased in T cells in patients with unstable angina 7 and strong immunoreactivity of RANKL was detected in vulnerable plaques and thrombus from ruptured coronary lesions. 5 Several lines of evidence suggest that RANKL, its receptor (RANK) and osteoprotegerin are involved in atherosclerotic lesion progression and plaque destabilization and calcification. 7, 8 We have also previously demonstrated additional vascular roles of RANKL in stimulating angiogenesis, expression of inflammatory adhesion molecules, and endothelial permeability. 9, 10 Although RANKL has been emerging as a risk marker for cardiovascular disease, 11 the epidemiological data are still limited to ascertain clear association between RANKL level and cardiovascular disease. 6 Nevertheless, RANKL appears to be correlated with plaque destabilization and thrombosis based on its role in vascular calcium deposition and its prominent expression in advanced lesions. 5, 7 In this study, we provide evidence for novel function of RANKL as a potential risk factor for atherothrombosis, demonstrating that RANKL significantly increases TF expression in macrophages, the major cellular component of atherosclerotic plaques.
Methods
Standard methods for semiquantitative RT-PCR, chromogenic assay, transfection of small interfering (si)RNA, infection of small hairpin RNA lentivirus, luciferase assay, electrophoretic mobility-shift assay, and Western blot are described in the expanded Methods section, available in the Online Data Supplement at http:// circres.ahajournals.org.
Results and Discussion

RANKL Upregulates TF Transcription in Macrophage Cells
TF is induced in macrophages, vascular smooth muscle cells (VSMCs), and endothelial cells (ECs) of atherosclerotic lesions and triggers thrombosis after plaque rupture. 2 Therefore, we investigated whether RANKL induces TF expression in those cell types. RANKL increased TF mRNA expression and its procoagulant activity specifically in mouse macrophage RAW 264.7 cells (Online Figure I and Figure 1A through 1C), and also in human monocytic leukemia THP-1 cells ( Figure 1D ; Online Figure II, A and B) . Moreover, TF antigen was increased on the surface of THP-1 cells in response to RANKL treatment (Online Figure II, C and D) . The possibility of endotoxin contamination in our RANKL protein was excluded by the LAL assay and experiment with commercially available RANKL protein (Online Figure III) . Taken together, our findings demonstrate that RANKL is a novel inducer of TF expression.
Along with TF increase in RANKL-treated macrophages, we also detected very faint bands representing alternatively Figure 1 . RANKL increases TF mRNA expression and activity. A and B, TF mRNA levels in RAW 264.7 cells after exposure to RANKL (3 g/mL) for the indicated times (A) or with indicated doses of RANKL for 2 hours (B), as assessed by semiquantitative RT-PCR analysis. C and D, Chromogenic assay of TF activity after RANKL (3 g/mL) treatment for 2 hours in RAW 264.7 cells (C) and THP-1 cells (D). E, The schematics of mouse TF promoter constructs. F, Luciferase activity was determined in RAW 264.7 cells transiently transfected with deletion mutants and treated with RANKL (3 g/mL) for 2 hours. *PϽ0.05; **PϽ0.01 (RANKLtreated vs untreated cells). spliced form of TF (asTF) in human and murine cells (Online Figure II , A). The asTF was initially reported as a soluble TF, but its procoagulant activity is still unclear. 12,13 RANKLinduced asTF might exert a biological effect in thrombosis. However, because the elucidation of the function of asTF is beyond this study, we focused on the effects of RANKL on full-length TF. The RANKL-induced increase in TF mRNA was abolished by pretreatment with actinomycin D, suggesting that RANKL increased TF mRNA by increasing transcription rather than by stabilizing preexisting mRNA (Online Figure IV) . To identify the key transcription factors involved in RANKLinduced TF transcription, we evaluated the luciferase activity of the deletion mutants depicted in Figure 1E . Deletion of a putative nuclear factor (NF)-B binding site decreased luciferase activity only slightly ( Figure 1F ). For a more elaborate discussion regarding involvement of NF-B in RANKL induced TF expression, see the expanded discussion section in the Online Supplemental Material. Interestingly, deletion of the AP-1 site and/or Egr-1 site resulted in a marked decrease in luciferase activity ( Figure 1F ). It implies that AP-1 and Egr-1 is of importance in RANKL-induced TF transcription.
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MAPK Pathways Control RANKL-Mediated TF Expression and Activity
Activated c-Jun NH 2 -terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 enhance the activity of c-Jun and Egr-1, respectively. We found that RANKL stimulated both JNK and ERK1/2 phosphorylation (Figure 2A ; Online To confirm whether JNK and ERK1/2 pathways are required for RANKL-induced TF expression and activity, we cotreated RAW 264.7 cells with RANKL and chemical inhibitors. The JNK inhibitor SP600125 reduced RANKLinduced TF mRNA levels ( Figure 3A ) and TF activity ( Figure  3C ). The MEK1 inhibitor U0126 produced similar results ( Figure 3B and 3D). These findings were confirmed via inhibition of phospho-c-Jun and Egr-1 in the nuclear fraction ( Figure 3E and 3F). Taken together, these results suggest that phospho-c-Jun and Egr-1 via JNK and ERK1/2 signaling respectively are involved in mediating the RANKL-induced TF expression in RAW 264.7 cells.
Knockdown of c-Jun and Egr-1 Attenuates RANKL-Induced TF Transcription
To confirm the results of chemical inhibitor experiments, we determined the effects of c-Jun and Egr-1 by using siRNA against Egr-1 and/or lentivirus-based small hairpin (sh)-cJun. Knockdown of either Egr-1 or c-Jun attenuated RANKLinduced TF expression and that of both genes demonstrated an additive effect ( Figure 3G and 3H). These results suggest that a multiprotein complex containing c-Jun and Egr-1 may play a key role in RANKL-induced TF expression in RAW 264.7 cells. 
RANKL Increases TF Activity by JNK/AP-1 and ERK1/2/Egr-1 Signaling in Mouse Peritoneal Macrophages
Finally, we determined the effect of RANKL on TF using the ex vivo system of mouse peritoneal macrophages. As expected, exposure of mouse peritoneal macrophages to RANKL increased TF mRNA expression ( Figure 4A ) and its activity ( Figure 4B ). In addition, RANKL induced phosphorylation of JNK and ERK1/2 ( Figure 4C ), the same signaling pathways involved in TF expression in RAW 264.7 cells. Also, RANKLinduced TF expression was attenuated by SP600125 and U0126 ( Figure 4D and 4E), suggesting the roles of JNK and ERK signaling in RANKL-induced TF expression in peritoneal macrophages.
In atherosclerotic plaques, TF is detected in macrophages and foam-cells as well as a lipid-rich core. 4 The level of TF is higher in plaques from symptomatic than asymptomatic patients and plaque thrombogenicity is directly correlated to their TF content. 3, 4 Given that RANKL is expressed by mast cells and T cells in activated plaques and its cognate receptor RANK is present in macrophages, 6 ligation of RANKL and its receptor on macrophage could contribute to upregulation of TF in advanced lesions. Our data show that RANKL can induce membrane-bound TF and enhance procoagulant activity in macrophages. Notably, strong immunostaining of RANKL was detected in vulnerable plaques as well as in thrombus material from the site of ruptured plaques. 7, 11 Thus, it is speculated that RANKL could participate in 2 ways at the later stage of atherosclerosis: by atherosclerotic plaque calcification 7, 8, 14 and subsequently by thrombus formation through strong induction of TF from macrophages.
We show that RANKL induces TF expression mainly via JNK/ERK1/2-mediated AP-1/Egr-1 signaling in macro- A and B) . TF activity was determined using a chromogenic assay (C and D). **PϽ0.01. Nuclear extracts were analyzed by Western blot (E and F). G and H, RAW 264.7 cells were infected with c-Jun small hairpin RNA lentivirus, followed by Egr-1 siRNA transfection. The cells were then treated for 2 hours with RANKL (3 g/mL), and knockdown was confirmed by Western blot (G). TF mRNA levels were determined by semiquantitative RT-PCR (H). *PϽ0.05. SC indicates nontargeting scrambled siRNA.
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phages. Also, our data indicate a potential role of NF-B in TF expression by RANKL. Interestingly, it has been shown that sphingomyelin synthase 2 deficiency in macrophages diminished NF-B and MAPK activation and reduced atherosclerosis in mice, 15 and Egr-1 in the procoagulant response was higher in apoE
mice. 16 This supports the pathway of RANKL-mediated TF expression in macrophages and further raises the likeliness of RANKL involvement in atherothrombosis. Given that NFAT (nuclear factor of activated T cells), which is responsible for the transcription of TF, is activated by RANKL, 17 we suggest that NFAT may also play a role in RANKL-mediated activation of TF. Considering our findings together with the previously identified role of RANKL as an endothelial activator 9, 10 and an inducer of VSMCs calcification via the bone morphogenetic protein 4 pathway, 8 ,14 RANKL appears to be multiply involved in vascular pathophysiology. Although current data are limited to conclude physiological and clinical relevance, our findings support the notion that RANKL could be a causable risk factor for cardiovascular diseases including atherosclerosis. 
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Novelty and Significance
What Is Known?
• Receptor activator of nuclear factor-B (RANKL) was initially found as a regulator of bone remodeling. Later studies suggest that it is also involved in stimulating angiogenesis and regulating vascular inflammation.
• RANKL and its cognate receptor (RANK) are strongly detected in vulnerable atherosclerotic plaques and thrombus from ruptured coronary lesions.
• Tissue factor (TF) is predominantly expressed in macrophages of atherosclerotic plaques and it acts as a risk factor for the initiation and progression of atherothrombosis.
What New Information Does This Article Contribute?
• RANKL is a strong inducer of TF in macrophages.
• RANKL-induced TF expression is mediated by cooperative action between AP-1 and Egr-1.
Although RANKL and RANK are highly expressed in vulnerable atherosclerotic lesions, the data demonstrating a clear association between RANKL and cardiovascular diseases, including atherosclerosis, are lacking. We attempted to further clarify the potential role of RANKL as a risk factor for cardiovascular disease. Our results demonstrate that RANKL significantly increases TF activity in macrophages. TF induction by RANKL was mediated by AP-1 and Egr-1 via JNK and ERK1/2 signaling. This study shows for the first time a significant link between RANKL and TF in macrophages leading to thrombus formation in cardiovascular diseases. Our findings suggest that the development of a RANKL antagonist may be a novel therapeutic strategy for the treatment of cardiovascular diseases, including atherosclerosis.
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Supplemental Material
Materials and Methods
Materials
Soluble RANKL (hCD8-conjugated form) was purified from Drosophila S2 cells as described 
Cell Culture
The murine RAW 264.7 cell line and human monocytic leukemia cell line (THP-1 cells)
were obtained from American Type Culture Collection (Manassas, VA). RAW 264.7 cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Karlsruhe, Germany) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . To induce macrophage-like differentiation, THP-1 cells were treated with 10 ng/mL phorbol-12-myristate-13-acetate (PMA) in RPMI 1640 medium (Gibco BRL) supplemented with penicillin (100 U/mL), streptomycin (100 μg/mL), and 10% heat-inactivated fetal bovine serum (FBS) for 2 days. The differentiated THP-1 cells were washed to remove undifferentiated cells and PMA, and then incubated for 1 day, as previously described. 
Gene
Forward Primer Reverse Primer
Mouse TF 5′-acagccagtaattcagcagt-3′ 5′-gtttctcccaggaaactctt-3′
Mouse c-Jun 5′-ccctatcgacatggagtct-3′ 5′-actttctgcttaagctgtgc-3′
Mouse Egr-1 5′-catgcgtaacttcagtcgta-3′ 5′-aggagaggagtaggaagtgg-3′
Mouse β-actin 5′-cgtctccggagtccatcaca-3′ 5′-tcctccgttgccggtccaca-3′
Human TF 5 5′-cgccgccaactggtagac-3′ 5′-tgcagtagctccaacagtgc-3′
Human GAPDH 5′-ccacccatggcaaattcc-3′ 5′-tcgctcctggaagatggtg-3′
Measurement of Tissue Factor (TF) Activity
Functional TF activity in RAW 264.7 cells, THP-1 cells, and peritoneal macrophages was determined with a previously described chromogenic assay. 
Reporter Gene Constructs and Luciferase Assay
To construct the TF luciferase reporter plasmids, we cloned the full (-230) mouse TF promoter into the pGL3-Basic vector (Promega). AP-1, NF-κB, and Sp1/Egr-1 deletion fragments were obtained by PCR amplification. RAW 264.7 cells were transfected with 1.5 µg DNA/well and control plasmid CMV-Renilla (0.5 μg/well) using MicroPorator (Digital Bio, Seoul, Korea) according to the manufacturer's protocol. After 24 hr, the cells were incubated with RANKL (3 μg/mL) for an additional 2 hr. Luciferase activity was measured with use of dual-luciferase assay kits (Promega)
according to the protocol as described by the manufacturer. Luciferase activity was normalized to CMV-Renilla activity to control for transfection efficiency.
Western Blot Analysis
The cells were treated with 3 μg/mL of RANKL. Whole cell lysates, nuclear extracts, or membrane-enriched fractions were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinyl difluoride membrane. Immunoreactive bands were visualized using chemiluminescence reagent (Amersham Pharmacia, Bucks, United Kingdom).
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift Assay
Cells were washed three times with ice-cold PBS and resuspended in 400 µL of buffer A PBS. 6 To detect the primary antibody, slides were incubated with Alexa Fluor 488 anti-mouse (dilution, 1:750) for 45 min at room temperature. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, 1 µg/mL; Sigma Aldrich). Fluorescent images were captured with the Carl Zeiss LSM 510 META confocal imaging system (magnification, ×1000). Relative levels of membrane TF were estimated from the fluorescence intensity of Alexa Fluor 488 dye (MetaMorph).
Subcellular Fractionation
After THP-1 cells were treated with 3 μg/mL of RANKL for 2 hr, membrane fractions were isolated using the Compartmental Protein Extraction Kit (Millipore Bioscience Research, Temecula, CA) according to the manufacturer's instructions.
LPS quantification
RANKL was processed with the reagents of the QCL-1000 LAL assay (BioWhitaker, MD) according to the manufacturer's instructions. Absorbance of the sample was determined at 405nm and the concentration of LPS was estimated with a standard curve.
Statistical Analysis
Data was analyzed by Student's t-test and expressed as mean ± standard deviation (SD). All experiments were performed at least three times, and representative results are shown.
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Online Results and Discussion
In Figure 1F , the deletion of NF-B binding region decreased the promoter activity only slightly. Since RANKL is a well-known NF-B activator, to clarify NF-B involvement in RANKL induced TF expression, we examined the endogenous activity of NF-B on TF promoter (p230, a full length promoter) after p65 knockdown. RANKL-mediated TF promoter activity was decreased to around 20% by the treatment of p65 siRNA (Online Figure VA) . It seems that the extent of decrease of TF promoter activity by p65 knockdown was still small as shown by the deletion of NF-B binding sites.
However, TF expression analyzed by semi-quantitative RT-PCR showed significant decrease on knockdown p65 (Online Figure VB) .
Thus we speculate that a contradiction between TF promoter assay and TF expression may be due to the range of TF promoter region we used in this study. As we have studied up to -870 from TF gene, we cannot exclude the possibility that there may be other NF-B binding sites or other sites to enhance NF-B activity. Taking together, the precise mechanism underlying NF-B binding at TF promoter needs to be further investigated. 
